7 9 9 1 4

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



作者优惠计划

Favored Author Program


很高兴为我们的作者提供一种切实的方法以支持开放获取,并鼓励教师和研究人员通过开放获取模式,尽可能广泛地推广他们的作品。


作者优惠计划的成员将获得:


文章发表费(APC) 10% 的折扣


这 10% 的折扣从您加入 “作者优惠计划” 之时开始,并将适用于之后提交的所有论文



*若要加入“作者优惠计划”,您需要已经在德孚医药出版社发表过论文,或为我们进行过同行评审。作者必须在提交论文之前注册该优惠计划,折扣不能追溯应用于已提交的论文




更多详情 >>



已发表论文

长非编码 RNA LINC01296 与前列腺癌的不良预后相关联,并且促进癌细胞的增殖和转移

 

Authors Wu J, Cheng G, Zhang C, Zheng Y, Xu H, Yang H, Hua L

Received 10 December 2016

Accepted for publication 21 February 2017

Published 27 March 2017 Volume 2017:10 Pages 1843—1852

DOI https://doi.org/10.2147/OTT.S129928

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Narasimha Reddy Parine

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza

Background/purpose: Long noncoding RNAs (lncRNAs) have emerged as important regulators and biomarkers of tumor development and progression. This study investigated the clinical significance, biological functions, and underlying mechanisms of long intergenic non-protein-coding RNA 1296 (LINC01296) in prostate cancer.
Materials and methods: LINC01296 expression in prostate cancer tissues and cell lines was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The correlation between LINC01296 expression and clinicopathologic characteristics of prostate cancer was analyzed using Kaplan–Meier analysis and the Cox proportional-hazard model. Small interfering RNA was used to suppress LINC01296, and knockdown efficiency was examined by qRT-PCR. Cell Counting Kit 8 assay, colony-formation assay, migration and invasion assays, and Western blot assay were used to explore the role of LINC01296 in tumor progression further.
Results: LINC01296-expression level was higher in prostate cancer tissues and prostate cancer cells than in adjacent nontumor tissues and immortalized normal prostate stromal WPMY1 cells. LINC01296 expression was correlated with preoperative prostate specific antigen (=0.002), lymph-node metastasis (=0.035), Gleason score (<0.001), and tumor stage (=0.036). Patients with higher LINC01296 expression displayed advanced clinical features and shorter biochemical recurrence-free survival time than those with lower LINC01296 expression. Multivariate analysis showed that LINC01296 expression was an independent predictor of biochemical recurrence-free survival in prostate cancer. Additionally, LINC01296 knockdown inhibited prostate cancer-cell proliferation, migration, and invasion, demonstrated in an in vitro study involving regulation of PI3K–Akt–mTOR signaling and epithelial–mesenchymal transition.
Conclusion: The results demonstrated that LINC01296 is a novel molecule involved in prostate cancer development and progression, and thus is a potential biomarker of prognosis.
Keywords: long noncoding RNA, prostate cancer, prognosis, proliferation, migration, invasion